WallStSmart
ALMS

Alumis Inc

NASDAQ: ALMS · HEALTHCARE · BIOTECHNOLOGY

$23.51
-6.52% today

Updated 2026-06-05

Market cap
$2.55B
P/E ratio
P/S ratio
304.09x
EPS (TTM)
$-1.78
Dividend yield
52W range
$3 – $31
Volume
1.2M

Alumis Inc (ALMS) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2022202320242025
Total assets$108.17M$89.61M$340.99M$411.94M
Cash & equivalents$25.61M$46.00M$169.53M$89.67M
Current assets$102.56M$53.36M$306.19M$318.23M
Total liabilities$303.41M$428.87M$80.89M$110.64M
Current liabilities$13.35M$20.87M$50.91M$73.32M
Long-term debt
Shareholder equity$-195.24M$-339.26M$260.10M$301.30M
Retained earnings$-209.32M$-364.32M$-658.55M$-901.88M
Accounts receivable$500000.00$722000.00$1.81M$2.08M
Inventory$-95000.00
Goodwill

Frequently asked questions

What is Alumis Inc's revenue?

Alumis Inc's trailing twelve-month revenue is $8.40M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is ALMS?

In its most recent fiscal year, ALMS ran a gross margin of 85.46%, an operating margin of -1,776.32%, and a net margin of -1,011.75%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ALMS generate?

ALMS produced $-370.18M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ALMS's balance sheet healthy?

ALMS holds $89.67M in cash and equivalents against — in long-term debt, on $301.30M of shareholder equity. That debt is best read against the cash flow the business throws off each year.